Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion Upfront in Retina Push

SentiSense · Published · Updated

Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront plus up to about $1.125 billion in milestones, roughly $3.3 billion in total. Ollin's lead drug OLN324, a bispecific antibody against VEGF and Ang2, is heading into Phase 3 for wet AMD and diabetic macular edema, and Blackstone will help fund that development.

JNJ agreed to acquire privately held Ollin Biosciences for $2.2 billion upfront, plus regulatory and commercial milestones of up to approximately $1.125 billion, putting the potential total at about $3.3 billion. A pre-announcement report of a $3.4 billion price is not supported by the company's own terms. The deal is expected to close before the end of 2026, subject to regulatory approvals.

The prize is OLN324, a bispecific antibody that targets two drivers of retinal disease, VEGF and Ang2, for wet age-related macular degeneration and diabetic macular edema. J&J describes it as a Phase 3 investigational antibody with potential for stronger and more durable disease control and longer intervals between injections. Ollin also has an earlier-stage program for thyroid eye disease. The retina market is led by entrenched injectables, so OLN324 will have to prove its case in late-stage trials.

J&J is sharing the development bill. In a separate agreement contingent on closing, Blackstone Life Sciences will pay J&J $750 million over multiple years to fund Phase 3 development of OLN324, in return for milestones and single-digit royalties. That structure limits J&J's near-term cash outlay beyond the upfront payment.

J&J has a limited footprint in retinal disease despite its large contact lens business, and the deal is framed as a way to strengthen its ophthalmology leadership. Investors will watch Phase 3 timelines and data for OLN324, the accounting treatment J&J discloses at closing, and how the asset fits alongside its existing vision portfolio.

Related Stocks

Powered by SentiSense - Intelligent Market Analysis